Compositions and the use thereof for treating or preventing rosacea

Active Publication Date: 2019-06-27
GALDERMA HLDG SA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0014]The invention provides an effective topical

Problems solved by technology

The pathogenesis of rosacea is complex and not yet completely understood.
However, these treatments do not allow to treat efficiently rosacea especially the inflammatory lesions and take several weeks to impr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example

Example 1: Evaluation of the Anti-Inflammatory Activity of Ivermectin and Diclofenac after a Single Topical Application in the Arachidonic Acid-Induced Mouse Ear Edema Test on Balb / c Mice

[0069]1) Material and Methods

Arachidonic acid is dissolved in a mixture of THF / Methanol at 4%.

Tested compounds were dissolved in arachidonic acid solution, at final concentration.

20 μl of the tested compound is dissolved in arachidonic acid solution and applied on the internal side of the right ear.

The ear thickness is measured at T=0 h, T+1 h, T+2 h, T+4 h.

THF / Methanol is used as vehicle control.

Indomethacin 5% is used as positive control and arachidonic acid at 4% in THF / Methanol is used as inductor of inflammation.

[0070]2) Results

Ear thickness measurement after 1 h demonstrated that the positive control with indomethacin at 5% inhibits the ear edema caused by arachidonic acid by 95%. Ivermectin 1% alone, reduces the ear edema by 56%. Diclofenac 1% alone reduces the ear edema 68%. The combination ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Percent by massaaaaaaaaaa
Percent by massaaaaaaaaaa
Percent by massaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a composition comprising a pharmaceutically acceptable carrier, at least one compound of the avermectin family, and at least one non-steroidal anti-inflammatory compound. The present invention further provides such composition for use in the treatment and/or the prevention of rosacea.

Description

[0001]The present invention concerns dermatologic field and relates to compositions and the use thereof for the treatment and / or prevention of rosacea.BACKGROUND OF THE INVENTION[0002]Rosacea is a common chronic and progressive inflammatory dermatosis associated with vasodilatation. Rosacea affects principally central part of the face and is characterized by facial flushes, facial erythema, papules, pustules, telangiectasia and sometimes ocular lesions and rhinophyma. Moreover these primary features are associated with a secondary neurogenic component, more specifically to a cutaneous hyperreactivity of face and neck skin, characterized by the apparition of skin redness, pruritus, feelings of itching, burning, stinging, and rough, flaky skin sensations.[0003]Rosacea is classified into four subtypes according to the degree of primary features, such as vasomotor flushing, persistent erythema, papules and pustules, telangiectasia, phymatous changes and ocular involvement.[0004]Erythema...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61K31/196A61K9/00A61P29/00A61P17/00
CPCA61K31/7048A61K31/196A61K9/0014A61P29/00A61P17/00A61K2300/00A61K9/107A61K31/19A61K31/60A61K45/06
Inventor JACOVELLA, JEANROYE, OLIVIERJOMARD, ANDRE
Owner GALDERMA HLDG SA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap